Physician profile
Jasmin Patel
NPI 1376076240
$92,576.30
in general payments reported to CMS, 2019-2025
22 companies · $61K in 2025
The $61K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,987 · 2024: $30K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Consulting Fee: $11K · Food and Beverage: $9,303 · Travel and Lodging: $4,640 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,427.00 |
| Consulting Fee | $11,067.00 |
| Food and Beverage | $9,302.76 |
| Travel and Lodging | $4,639.88 |
| Education | $139.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $48,397.82 | 2023-2025 | |
| Biogen, INC. | $27,917.02 | 2023-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $5,910.12 | 2023-2025 | |
| Emd Serono, INC. | $3,671.09 | 2023-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $1,875.34 | 2023-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $1,037.99 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Celgene Corporation | $864.82 | 2023-2025 | Zeposia |
| Genzyme Corporation | $698.51 | 2023-2025 | |
| Abbvie INC. | $596.43 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $369.28 | 2024-2025 | Zeposia |
| Amgen INC. | $326.63 | 2024-2025 | Uplizna |
| Genentech, INC. | $277.81 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Mallinckrodt Hospital Products INC. | $173.35 | 2024-2025 | Acthar |
| Lundbeck LLC | $130.98 | 2024-2025 | Vyepti |
| Ani Pharmaceuticals, INC. | $103.73 | 2024-2025 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $65.28 | 2025 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $44.20 | 2023-2024 | Nuedexta |
| Pfizer INC. | $38.01 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $35.53 | 2024-2025 | Ampyra, Xeomin |
| Cycle Pharmaceuticals INC | $14.47 | 2025 | Tascenso Odt |
| Horizon Therapeutics Plc | $14.46 | 2023 | Uplizna |
| Acorda Therapeutics, INC | $13.43 | 2023 | Ampyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.